IL122385A - Composition for sustained release of human growth hormone - Google Patents

Composition for sustained release of human growth hormone

Info

Publication number
IL122385A
IL122385A IL12238596A IL12238596A IL122385A IL 122385 A IL122385 A IL 122385A IL 12238596 A IL12238596 A IL 12238596A IL 12238596 A IL12238596 A IL 12238596A IL 122385 A IL122385 A IL 122385A
Authority
IL
Israel
Prior art keywords
composition
sustained release
hgh
biologically active
polymer
Prior art date
Application number
IL12238596A
Other languages
English (en)
Other versions
IL122385A0 (en
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/473,544 external-priority patent/US5654010A/en
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of IL122385A0 publication Critical patent/IL122385A0/xx
Publication of IL122385A publication Critical patent/IL122385A/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL12238596A 1995-06-07 1996-06-03 Composition for sustained release of human growth hormone IL122385A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/473,544 US5654010A (en) 1992-12-02 1995-06-07 Composition for sustained release of human growth hormone
US08/477,725 US5667808A (en) 1992-12-02 1995-06-07 Composition for sustained release of human growth hormone
PCT/US1996/008086 WO1996040072A2 (en) 1995-06-07 1996-06-03 Composition for sustained release of human growth hormone

Publications (2)

Publication Number Publication Date
IL122385A0 IL122385A0 (en) 1998-06-15
IL122385A true IL122385A (en) 2001-01-11

Family

ID=27044171

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12238596A IL122385A (en) 1995-06-07 1996-06-03 Composition for sustained release of human growth hormone

Country Status (22)

Country Link
EP (1) EP0831787B1 (sk)
JP (1) JPH11506740A (sk)
CN (1) CN1102854C (sk)
AT (1) ATE204468T1 (sk)
AU (1) AU708756B2 (sk)
BR (1) BR9608542A (sk)
CA (1) CA2223436A1 (sk)
CZ (1) CZ288147B6 (sk)
DE (1) DE69614685T2 (sk)
DK (1) DK0831787T3 (sk)
ES (1) ES2161366T3 (sk)
HK (1) HK1009089A1 (sk)
HU (1) HUP9900870A3 (sk)
IL (1) IL122385A (sk)
MX (1) MX9709698A (sk)
NO (1) NO316104B1 (sk)
NZ (1) NZ310644A (sk)
PL (1) PL184531B1 (sk)
PT (1) PT831787E (sk)
RU (1) RU2161502C2 (sk)
SK (1) SK281571B6 (sk)
WO (1) WO1996040072A2 (sk)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001331A2 (en) * 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1953173B1 (en) 1999-06-15 2009-11-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
CA2490853A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1897947B1 (en) 1999-12-23 2012-01-18 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
CN1425066B (zh) 2000-01-13 2010-05-26 杰南技术公司 新的stra6多肽
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
JP2003528149A (ja) 2000-03-24 2003-09-24 ジェネンテック・インコーポレーテッド 軟骨性疾患の治療のためのインスリンの使用
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US8637077B2 (en) 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
US7271150B2 (en) 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP1397155B1 (en) 2001-06-21 2015-09-30 Genentech, Inc. Sustained release formulation
CA2477249A1 (en) 2002-02-25 2003-09-04 Genentech, Inc. Novel type-1 cytokine receptor glm-r
WO2004091658A1 (en) 2003-04-04 2004-10-28 Genentech, Inc. High concentration antibody and protein formulations
EP2093570A1 (en) 2003-06-06 2009-08-26 Genentech, Inc. Modulating the interaction between HGF beta chain and c-met
SI2784084T2 (sl) 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
EP1692178A1 (en) 2003-12-11 2006-08-23 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
KR101204286B1 (ko) 2004-03-30 2012-11-26 엔에스진 에이/에스 성장 인자 ＮｓＧ33의 치료학적 용도
KR101242543B1 (ko) 2004-10-27 2013-03-22 유니버시티 오브 덴버 부신피질 자극 호르몬 유사체 및 관련 방법
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
KR20070095921A (ko) 2004-12-10 2007-10-01 탈리마 테라퓨틱스 인코포레이티드 조갑 단위의 상태를 치료하기 위한 조성물 및 방법
JP2008541781A (ja) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッド 異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
KR20140139618A (ko) 2005-06-21 2014-12-05 조마 (유에스) 엘엘씨 ＩＬ-１β 결합성 항체 및 그의 단편
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
CA2620903A1 (en) 2005-08-24 2007-03-01 The Rockefeller University Ply-gbs mutant lysins
EP1962584A2 (en) 2005-11-21 2008-09-03 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
BRPI0621124A2 (pt) 2005-12-22 2011-11-29 Genentech Inc métodos para recuperação de uma proteìna de ligação à heparina
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
EP2389946A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
ES2385261T3 (es) 2006-04-10 2012-07-20 Genentech, Inc. Moduladores de PDZ Disheveled
CA2649387A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
KR101524880B1 (ko) * 2006-08-31 2015-06-01 노파르티스 아게 Ｈｇｈ를 포함하는 경구 전달용 제약 조성물
JP5645409B2 (ja) 2006-12-20 2014-12-24 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連疾患の治療方法
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
KR20100058541A (ko) * 2007-08-15 2010-06-03 아뮤닉스 인코포레이티드 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법
RU2018100129A (ru) 2007-12-20 2019-02-20 Ксома (Сша) Ллс Способы лечения подагры
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
JP6016636B2 (ja) 2009-10-15 2016-10-26 ジェネンテック， インコーポレイテッド 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
JP5878477B2 (ja) 2010-01-15 2016-03-08 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー 骨の治癒を加速するためのバナジウム化合物の使用
JP5937059B2 (ja) 2010-03-22 2016-06-22 ジェネンテック， インコーポレイテッド タンパク質含有製剤の安定化に有用な組成物及び方法
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
AU2011270828B2 (en) 2010-06-24 2015-09-24 Genentech, Inc. Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
ES2584068T3 (es) 2010-10-01 2016-09-23 Nsgene A/S Uso de meteorina para el tratamiento de alodinia, hiperalgesia, dolor espontáneo y dolor fantasma
US9345764B2 (en) 2010-10-08 2016-05-24 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
JP5913326B2 (ja) 2010-10-08 2016-04-27 シャンハイ クーシン バイオテック カンパニー，リミテッド モエシン断片の診断的および治療的使用
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
CN102875683B (zh) * 2011-07-11 2014-06-11 旭华（上海）生物研发中心有限公司 长效重组人生长激素的Fc融合蛋白
WO2013066866A1 (en) 2011-10-31 2013-05-10 Genentech, Inc. Antibody formulations
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
CN104411717A (zh) 2012-01-09 2015-03-11 斯克利普斯研究所 具有超长cdr3s的人源化抗体
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
CN105377355A (zh) 2013-03-14 2016-03-02 拇趾公司 治疗甲单元的感染、疾病或病症的方法
CN105283196B (zh) 2013-03-15 2018-10-12 贝丝以色列女执事医疗中心 用于产生和使用构象-特异性抗体的方法和组合物
CN111518199A (zh) 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CA2924109A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
ES2845924T3 (es) 2013-10-15 2021-07-28 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
AU2014337385B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Chimeric antigen receptor T cell switches and uses thereof
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
CN109328069B (zh) 2016-04-15 2023-09-01 亿一生物医药开发(上海)有限公司 Il-22在治疗坏死性小肠结肠炎中的用途
KR102613430B1 (ko) 2016-10-19 2023-12-18 더 스크립스 리서치 인스티튜트 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
KR20210145152A (ko) 2019-04-01 2021-12-01 제넨테크, 인크. 단백질-함유 제제들의 안정화를 위한 조성물들 및 방법들
JP2022544549A (ja) 2019-08-12 2022-10-19 ピュリノミア バイオテック， インコーポレイテッド Ｃｄ３９発現細胞のａｄｃｃ標的化を介してｔ細胞媒介性免疫応答を促進及び増強するための方法及び組成物
EP4048405A2 (en) 2019-10-24 2022-08-31 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
CA3217865A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
KR20240006581A (ko) 2021-05-06 2024-01-15 호바 세라퓨틱스 에이피에스 화학요법-유도된 신경병성 통증의 예방 및 치료
CA3239550A1 (en) 2021-12-10 2023-06-15 Kenneth Petersen Treatment of nociceptive pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
DE69329295T2 (de) * 1992-12-02 2001-03-15 Alkermes Controlled Therapeutics, Inc. Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
ES2151079T3 (es) * 1994-09-09 2000-12-16 Takeda Chemical Industries Ltd Preparacion de liberacion sostenida que contiene una sal metalica de un peptido.

Also Published As

Publication number Publication date
SK167197A3 (en) 1998-06-03
DE69614685T2 (de) 2002-06-27
ES2161366T3 (es) 2001-12-01
PT831787E (pt) 2002-02-28
DE69614685D1 (de) 2001-09-27
NO975708D0 (no) 1997-12-05
NO316104B1 (no) 2003-12-15
CZ390797A3 (cs) 1998-07-15
HUP9900870A3 (en) 2001-04-28
CN1102854C (zh) 2003-03-12
MX9709698A (es) 1998-07-31
DK0831787T3 (da) 2001-12-17
BR9608542A (pt) 1999-11-30
WO1996040072A3 (en) 1997-01-23
HK1009089A1 (en) 1999-09-10
HUP9900870A2 (hu) 1999-09-28
RU2161502C2 (ru) 2001-01-10
NO975708L (no) 1998-02-05
CZ288147B6 (en) 2001-05-16
AU6146996A (en) 1996-12-30
CA2223436A1 (en) 1996-12-19
ATE204468T1 (de) 2001-09-15
IL122385A0 (en) 1998-06-15
PL184531B1 (pl) 2002-11-29
CN1187120A (zh) 1998-07-08
NZ310644A (en) 1999-08-30
WO1996040072A2 (en) 1996-12-19
PL323832A1 (en) 1998-04-27
EP0831787B1 (en) 2001-08-22
JPH11506740A (ja) 1999-06-15
SK281571B6 (sk) 2001-05-10
EP0831787A2 (en) 1998-04-01
AU708756B2 (en) 1999-08-12

Similar Documents

Publication Publication Date Title
IL122385A0 (en) Composition for sustained release of human growth hormone
MX9709699A (es) Composicion para la liberacion sostenida de eritropoyetina no agregada.
DE3853853T2 (de) Verabreichungsformen für Pharmaka.
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
EP1570823A3 (en) Substained analgesia achieved with buprenorphine
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
CA2474698A1 (en) Polymer-based compositions for sustained release
EP1637164A3 (en) Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5972384A (en) Use of biologically active glass as a drug delivery system
JPH07187994A (ja) 薬物放出制御製剤
EP1011637A4 (en) MODULATION OF DRUG LOAD IN MULTIFICULAR LIPOSOMES
AU7004194A (en) Drug system
US5342622A (en) Subdermal biocompatible implants
SK281461B6 (sk) Kolagénový prípravok na riadené uvoľňovanie účinných látok
AU5673399A (en) Compositions and methods for treating intracellular infections
WO2020166820A1 (ko) 피나스테라이드를 포함하는 마이크로 입자를 함유한 피하 주사용 조성물
EP0050650A1 (en) Prolonged action drug formulation
JPH0513130B2 (sk)
JPH06507634A (ja) 局所炎症反応の放出制御型薬物送達手段としての設計
Lim Development of Local Drug Delivery System: Prolonged Sciatic Nerve Blockade From Biodegradable Microspheres

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees